Reframe Daily: OTC nose spray cut COVID; gentler brain-bleed surgery; Angelman gene switch

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Scientists turned on the missing Angelman gene in animals; tiny bubbles and sound delivered antibodies into the brain; surgeons spotted a live brain signal that tells Parkinson’s from essential tremor; a gentler surgery helped people with brain bleeds in a randomized study; and an over-the-counter nose spray lowered COVID infections in a trial.

Christin’s note: no video today because my phone got wet in the rain and it won’t let me charge it until it’s dried out 😅…

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: An over-the-counter allergy nose spray lowered the chance of getting COVID in a randomized trial—easy to use and already on pharmacy shelves.

Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (available OTC in the U.S. now; off-label for prevention while larger confirmatory trials and labeling catch up).

Good news: A less-invasive surgery for bleeding strokes helped patients in a randomized trial, which could mean better recovery where hospitals can offer it.

Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage: The MIND Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂 (positive human RCT; tools exist in some U.S. centers, but wider adoption needs guideline updates and training).

Good news: Doctors recorded live brain signals and found a serotonin pattern that separates Parkinson’s disease from essential tremor—this could lead to faster, clearer diagnoses.

Caudate serotonin signaling during social exchange distinguishes essential tremor and Parkinson’s disease patients

Market readiness: 🙂🙂 (human intra-op study; needs validation and a clinically deployable test).

Good news: Scientists delivered antibodies into the brain by opening the blood-brain barrier with sound and tiny bubbles—aiming to treat tough brain diseases.

Precise antibody delivery to the brain via nanobubble-actuated focused ultrasound

Market readiness: 🙂🙂 (preclinical platform; next step is first-in-human safety testing).

Good news: A gene-therapy strategy switched on the “silent” copy of a key brain gene in Angelman syndrome models, pointing to a future one-shot treatment.

AAV-dCas9 vector unsilences paternal Ube3a in neurons by impeding Ube3a-ATS transcription

Market readiness: 🙂🙂 (strong results in cells and mice; human trials still ahead).

Thank you for taking the time to take care of yourself and your loved ones.